Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors

PR Newswire February 21, 2019

Antibody Candidates Targeting Parkinson’s Disease Identified

Stockhouse Editorial February 12, 2019

Parkinson's Disease: ProMIS Neurosciences Identifies Several Antibody Drug Candidates Showing Best-in-Class Selectivity for Toxic Forms of Alpha-Synuclein Compared to other Therapeutic Antibodies in Development

Canada NewsWire February 12, 2019

Parkinson's Disease: ProMIS Neurosciences Identifies Several Antibody Drug Candidates Showing Best-in-Class Selectivity for Toxic Forms of Alpha-Synuclein Compared to other Therapeutic Antibodies in Development

Canada NewsWire February 12, 2019

Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease

Canada NewsWire January 31, 2019

Shooting to the Top: HUGE Growth Numbers for Esports

Jeff Nielson January 28, 2019

ProMis Completes $2.2 Million Private Placement

Stockhouse Editorial January 23, 2019

ProMIS Neurosciences Completes Private Placement of Units

Canada NewsWire January 23, 2019

ProMIS Neurosciences Heading to NobleCon15 & CanTech

Stockhouse Editorial January 17, 2019

ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences

Canada NewsWire January 17, 2019

ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China Focus@JPMWeek

Canada NewsWire December 18, 2018

ProMIS Names Neuroscientist to Scientific Advisory Board

Stockhouse Editorial December 17, 2018

ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board

Canada NewsWire December 17, 2018

ProMIS Highlights Advancements Made in 2018

Stockhouse Editorial November 20, 2018

ProMIS Neurosciences Issues Year-to Date Update, Highlighting 2018 Accomplishments

Canada NewsWire November 20, 2018

ProMIS Neurosciences Announces Third Quarter 2018 Results

Canada NewsWire November 13, 2018

ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease

Canada NewsWire November 6, 2018

ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer's Disease and Other Dementias

Canada NewsWire October 31, 2018

ProMIS: New Focal Points in Advanced Parkinson’s Research

Featured Press Release October 11, 2018

ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson's Disease

Canada NewsWire October 11, 2018